[{"orgOrder":0,"company":"Universite de Sherbrooke Department of Medicine","sponsor":"Aker BioMarine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"||DGAT","graph1":"Neurology","graph2":"Preclinical","graph3":"Universite de Sherbrooke Department of Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine","highestDevelopmentStatusID":"4","companyTruncated":"Universite de Sherbrooke Department of Medicine \/ Aker BioMarine"},{"orgOrder":0,"company":"North-West University, South Africa","sponsor":"Swiss Federal Institute of Technology | MRC South Africa | Unilever","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH AFRICA","productType":"Dietary Supplement","year":"2010","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Hematology","graph2":"Undisclosed","graph3":"North-West University, South Africa","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"North-West University, South Africa \/ Swiss Federal Institute of Technology | MRC South Africa | Unilever","highestDevelopmentStatusID":"1","companyTruncated":"North-West University, South Africa \/ Swiss Federal Institute of Technology | MRC South Africa | Unilever"},{"orgOrder":0,"company":"Universidad de Granada","sponsor":"Puleva Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Phase II\/ Phase III","graph3":"Universidad de Granada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad de Granada \/ Puleva Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Universidad de Granada \/ Puleva Biotech"},{"orgOrder":0,"company":"University of Leeds","sponsor":"The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"University of Leeds","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Leeds \/ The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union","highestDevelopmentStatusID":"1","companyTruncated":"University of Leeds \/ The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Royal DSM \/ Syneos Health"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Mead Johnson Nutrition","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Mead Johnson Nutrition","highestDevelopmentStatusID":"1","companyTruncated":"University of Alabama at Birmingham \/ Mead Johnson Nutrition"},{"orgOrder":0,"company":"Mead Johnson Nutrition","sponsor":"International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Dietary Supplement","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Mead Johnson Nutrition","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mead Johnson Nutrition \/ International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Mead Johnson Nutrition \/ International Peace Maternity and Child Health Hospital | Chinese Academy of Sciences"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Dietary Supplement","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"DHA level","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"15","companyTruncated":"Lobe Sciences \/ Pentec Health"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Hofseth BioCare","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Dietary Supplement","year":"2021","type":"Partnership","leadProduct":"DHA","moa":"||DHA level","graph1":"Immunology","graph2":"Undisclosed","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Catalent Pharma Solutions \/ Hofseth BioCare","highestDevelopmentStatusID":"1","companyTruncated":"Catalent Pharma Solutions \/ Hofseth BioCare"},{"orgOrder":0,"company":"Retrotope","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Retrotope \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Retrotope \/ Undisclosed"},{"orgOrder":0,"company":"Carol Fabian","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Dietary Supplement","year":"2015","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Neurology","graph2":"Phase I","graph3":"Carol Fabian","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Carol Fabian \/ Royal DSM","highestDevelopmentStatusID":"6","companyTruncated":"Carol Fabian \/ Royal DSM"},{"orgOrder":0,"company":"Danone","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Iron","moa":"||Hemoglobin (HB)","graph1":"Hematology","graph2":"Approved FDF","graph3":"Danone","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Danone \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Danone \/ Undisclosed"},{"orgOrder":0,"company":"Shandong Sibote Biotechnology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Neurology","graph2":"Undisclosed","graph3":"Shandong Sibote Biotechnology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shandong Sibote Biotechnology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shandong Sibote Biotechnology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"IRCCS Eugenio Medea","sponsor":"DMF srl (Dietetic Metabolic Food)","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"IRCCS Eugenio Medea","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IRCCS Eugenio Medea \/ DMF srl (Dietetic Metabolic Food)","highestDevelopmentStatusID":"10","companyTruncated":"IRCCS Eugenio Medea \/ DMF srl (Dietetic Metabolic Food)"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Undisclosed","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Royal DSM","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ Royal DSM"},{"orgOrder":0,"company":"Micelle BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Micelle BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Micelle BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Micelle BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Unity Health Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Undisclosed","graph2":"Phase I","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Unity Health Toronto","highestDevelopmentStatusID":"6","companyTruncated":"University of Toronto \/ Unity Health Toronto"},{"orgOrder":0,"company":"Walter Reed National Military Medical Center","sponsor":"National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Immunology","graph2":"Undisclosed","graph3":"Walter Reed National Military Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"1","companyTruncated":"Walter Reed National Military Medical Center \/ National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"University of Cincinnati \/ Royal DSM","highestDevelopmentStatusID":"10","companyTruncated":"University of Cincinnati \/ Royal DSM"},{"orgOrder":0,"company":"Sarah Keim","sponsor":"Allen Foundation Inc. | March of Dimes | Cures Within Reach | Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"DHA","moa":"Peroxisome proliferator-activated receptor alpha; Prostaglandin G\/H synthase 1; Prostaglandin G\/H synthase 2; Peroxisome proliferator-activated receptor gamma; Retinoic acid receptor RXR-alpha; Retinoic acid receptor RXR-beta; Retinoic acid receptor RXR-gamma; Sterol regulatory element-binding protein 1; Myc proto-oncogene protein","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Sarah Keim","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarah Keim \/ Allen Foundation Inc. | March of Dimes | Cures Within Reach | Health Resources and Services Administration","highestDevelopmentStatusID":"11","companyTruncated":"Sarah Keim \/ Allen Foundation Inc. | March of Dimes | Cures Within Reach | Health Resources and Services Administration"}]

Find Clinical Drug Pipeline Developments & Deals for Docosahexaenoic Acid

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Shandong Sibote Biotechnology Co., Ltd.

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Shandong Sibote Biotechnology Co., Ltd.

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Docosahexaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition Disorders.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 01, 2024

                          Lead Product(s) : DHA

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          University of Toronto

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Toronto

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Docosahexaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 05, 2024

                          Lead Product(s) : DHA

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Unity Health Toronto

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          University of Alabama at Birmingham

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Alabama at Birmingham

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : DHA is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Infant Nutrition Disorders.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 16, 2024

                          Lead Product(s) : DHA

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Sponsor : Mead Johnson Nutrition

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Pentec will receive the exclusive rights to distribute Altemia (docosahexaenoic acid ethyl ester), a proprietary oral formulation of emulsified docohexanoic acid, clinically evaluated to restore DHA levels and help reduce inflammation associated with SCD...

                          Product Name : Altemia

                          Product Type : Dietary Supplement

                          Upfront Cash : Undisclosed

                          May 17, 2023

                          Lead Product(s) : DHA

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Pentec Health

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Aptamil (Iron) First Infant Milk Stage 1(This infant formula is appropriate for most infants and meets U.S. nutrient requirements, but it may not be suitable for infants born prematurely, or with a low birth weight.

                          Product Name : Aptamil

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          June 17, 2022

                          Lead Product(s) : Iron,DHA

                          Therapeutic Area : Hematology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : The partnership will see Catalent use its proprietary OptiGel® DR technology to encapsulate OmeGo (docosahexaenoic acid), HBC’s unique fish oil derived from sustainable, traceable, and fresh Norwegian Atlantic salmon.

                          Product Name : OmeGo

                          Product Type : Dietary Supplement

                          Upfront Cash : Undisclosed

                          May 12, 2021

                          Lead Product(s) : DHA,Icosapent Ethyl

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : Hofseth BioCare

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          Universite de Sherbrooke Department of Medicine

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Universite de Sherbrooke Department of Medicine

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Details : Université de Sherbrooke in Canada will test if LYSOVETA, Aker BioMarine’s new delivery platform based on LPC-bound EPA/DHA from krill, is more effective in increasing the concentration of DHA in the brain and improving cognition.

                          Product Name : Lysoveta

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          February 15, 2021

                          Lead Product(s) : Icosapent Ethyl,DHA

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Aker BioMarine

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Comapny's first D-PUFA drug candidate in development, RT001, has shown robust safety in over 50 patient years of oral dosing, and we expect RT011 to have a similar safety profile.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          July 21, 2020

                          Lead Product(s) : DHA

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Walter Reed National Military Medical Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Walter Reed National Military Medical Center

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : DHA

                          Therapeutic Area : Immunology

                          Study Phase : Undisclosed

                          Sponsor : National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Docosahexaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Inflammation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          August 28, 2019

                          Lead Product(s) : DHA

                          Therapeutic Area : Immunology

                          Highest Development Status : Undisclosed

                          Sponsor : National Institutes of Health | Royal DSM | National Institute on Alcohol Abuse and Alcoholism

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          University of Leeds

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          University of Leeds

                          Country arrow
                          OTS 2025
                          Not Confirmed

                          Lead Product(s) : DHA

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Study Phase : Undisclosed

                          Sponsor : The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : DHA is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Metabolic Syndrome.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          May 20, 2019

                          Lead Product(s) : DHA

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : The Leeds Teaching Hospitals NHS Trust | AdWare Research Ltd. | University of Bologna | European Union

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank